A First in Human Study of STT-5058, an Antibody That Binds ApoC3
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
A First in Human Study of STT-5058, an Antibody That Binds ApoC3, investigating single and
multiple ascending intravenous doses and ascending subcutaneous doses of STT-5058 in
otherwise healthy volunteers with elevated triglyceride levels